Sichuan Biokin Pharmaceutical Co. Ltd. A
Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, production, and supply of biomedicine in the fields of antibody drug conjugate, guidance navigation and control, and antibody radionuclide conjugate in China and internationally. It offers anesthesia, parenteral nutrition, anti-infectives, pediatrics, and traditional Chinese medicines. The company was founded in 1996 … Read more
Market Cap & Net Worth: Sichuan Biokin Pharmaceutical Co. Ltd. A (688506)
Sichuan Biokin Pharmaceutical Co. Ltd. A (SHG:688506) has a market capitalization of $14.48 Billion (CN¥106.24 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #4296 globally and #431 in its home market, demonstrating a 0.97% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sichuan Biokin Pharmaceutical Co. Ltd. A's stock price CN¥257.33 by its total outstanding shares 412873817 (412.87 Million).
Sichuan Biokin Pharmaceutical Co. Ltd. A Market Cap History: 2023 to 2026
Sichuan Biokin Pharmaceutical Co. Ltd. A's market capitalization history from 2023 to 2026. Data shows growth from $7.87 Billion to $14.48 Billion (92.38% CAGR).
Sichuan Biokin Pharmaceutical Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sichuan Biokin Pharmaceutical Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.85x
Sichuan Biokin Pharmaceutical Co. Ltd. A's market cap is 1.85 times its annual revenue
1.01x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
2.91x
Sichuan Biokin Pharmaceutical Co. Ltd. A's market cap is 2.91 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $7.87 Billion | $561.87 Million | -$780.50 Million | 14.01x | N/A |
| 2024 | $10.79 Billion | $5.82 Billion | $3.71 Billion | 1.85x | 2.91x |
Competitor Companies of 688506 by Market Capitalization
Companies near Sichuan Biokin Pharmaceutical Co. Ltd. A in the global market cap rankings as of March 18, 2026.
Key companies related to Sichuan Biokin Pharmaceutical Co. Ltd. A by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Sichuan Biokin Pharmaceutical Co. Ltd. A Historical Marketcap From 2023 to 2026
Between 2023 and today, Sichuan Biokin Pharmaceutical Co. Ltd. A's market cap moved from $7.87 Billion to $ 14.48 Billion, with a yearly change of 92.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥14.48 Billion | -20.36% |
| 2025 | CN¥18.18 Billion | +68.52% |
| 2024 | CN¥10.79 Billion | +37.05% |
| 2023 | CN¥7.87 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Sichuan Biokin Pharmaceutical Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.48 Billion USD |
| MoneyControl | $14.48 Billion USD |
| MarketWatch | $14.48 Billion USD |
| marketcap.company | $14.48 Billion USD |
| Reuters | $14.48 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.